GlassScriptPhysician profile
Debbie Snodgrass
NPI 1780175166
$13,235.31
in general payments reported to CMS, 2019-2025
35 companies · $2,823 in 2025
The $2,823 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,162 · 2022: $2,280 · 2023: $2,956 · 2024: $3,014 · 2025: $2,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,640 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,639.88 |
| Education | $153.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,524.18 | 2021-2025 | Evenity, Prolia, Tavneos |
| Aurinia Pharma U.S., INC. | $1,713.90 | 2021-2025 | Lupkynis |
| Abbvie INC. | $1,588.78 | 2021-2025 | |
| Janssen Biotech, INC. | $935.33 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $896.83 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $680.82 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $610.16 | 2021-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $479.77 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $422.42 | 2021-2025 | Taltz |
| Glaxosmithkline, LLC. | $406.07 | 2021-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $400.33 | 2023-2025 | Idacio, Tyenne |
| Radius Health, INC. | $377.95 | 2021-2025 | Tymlos |
| Organon LLC | $374.83 | 2023-2025 | Hadlima, Renflexis |
| Ucb, INC. | $352.13 | 2021-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $216.54 | 2021-2025 | Saphnelo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $202.11 | 2021-2025 | Orencia |
| Actelion Pharmaceuticals US, INC. | $159.91 | 2021 | |
| Genentech USA, INC. | $154.40 | 2021-2025 | Actemra, Gazyva |
| Sobi, INC | $92.26 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $85.88 | 2022 | |
| Alexion Pharmaceuticals, INC. | $67.64 | 2022-2025 | Strensiq |
| Teva Pharmaceuticals USA, INC. | $67.57 | 2023-2024 | Truxima, Simlandi |
| Idorsia Pharmaceuticals US INC | $65.32 | 2022-2023 | Quviviq |
| Octapharma USA, INC. | $60.00 | 2024-2025 | Octagam Immune Globulin (Human) |
| Daiichi Sankyo INC. | $40.80 | 2025 | Injectafer |
| Horizon Therapeutics Plc | $39.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.46 | 2023-2025 | Cyltezo, Ofev |
| Grifols USA, LLC | $35.95 | 2022-2023 | Gamunex-C |
| Blueprint Medicines Corporation | $33.33 | 2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $23.99 | 2023 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Tersera Therapeutics LLC | $17.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.31 | 2023 | Seglentis |
| Celltrion USA INC. | $16.14 | 2023 | Yuflyma |
| Sandoz INC. | $16.11 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Snodgrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.